Table 1. General characteristics of the included systematic reviews.

First Author/Publication year	Source	Search date up to	Interventiona	Prophy-laxisb	Treatmentb	Effect on flu related compli-cationsb	Adverse eventsb	Target groups	Unpublish-ed trials	Lan-guage restric-tions
Burch, 2009 [8]	HTA UK	Nov 2007	A/O/Z		N = 34	N = 19	N = 19	All ages and at-risk groups	yes	yes
Deonandan, 2007 [19]	HTA Canada	Aug 2006	O/Z	N = 11			N = 11	All ages and at-risk groups	no	no
Falagas, 2010 [20]	J Antimicrob Chemother	Sept 2009	O/Z			N = 11	N = 9	All ages and at-risk groups	no	yes
Jackson, 2011 [21]	J Infect	August 2009	A/O/Z	N = 12			N = 3	All ages and at-risk groups	no	yes
Jagannath, 2010 [16]	Cochrane SR	August 2009	O/Z		N = 0	N = 0	N = 0	Persons with cystic fibrosis	yes	no
Jefferson, 2012 [10]	Cochrane SR	April 2011	O/Z/P	N = 6	N = 19	N = 8	N = 18	Healthy adults/mixed populations/children	yes	no
Khazeni, 2009 [22]	Ann Intern Med	June 2009	O/Z	N = 6			N = 6	All ages and at-risk groups	no	no
Wang, 2012 [17]	Cochrane SR	Jan 2012	O/Z/L	N = 3	N = 6	N = 6	N = 9	Children healthy and at risk	no	no
Tappenden, 2009 [18]	HTA UK	July 2007	A/O/Z	N = 15			N = 0	All ages and at-risk groups	yes	yes

^aA = amantadine; O = oseltamivir; Z = zanamivir; P = peramivir; L = laninamivir.

^bN = number of trials included in SR.